[1]
Pena AB, Caviness JN. Physiology-Based Treatment of Myoclonus. Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics. 2020 Oct:17(4):1665-1680. doi: 10.1007/s13311-020-00922-6. Epub
[PubMed PMID: 32910414]
[2]
van der Veen S, Zutt R, Klein C, Marras C, Berkovic SF, Caviness JN, Shibasaki H, de Koning TJ, Tijssen MAJ. Nomenclature of Genetically Determined Myoclonus Syndromes: Recommendations of the International Parkinson and Movement Disorder Society Task Force. Movement disorders : official journal of the Movement Disorder Society. 2019 Nov:34(11):1602-1613. doi: 10.1002/mds.27828. Epub 2019 Oct 4
[PubMed PMID: 31584223]
[3]
Caviness JN. Myoclonus. Continuum (Minneapolis, Minn.). 2019 Aug:25(4):1055-1080. doi: 10.1212/CON.0000000000000750. Epub
[PubMed PMID: 31356293]
[5]
Lange LM, Gonzalez-Latapi P, Rajalingam R, Tijssen MAJ, Ebrahimi-Fakhari D, Gabbert C, Ganos C, Ghosh R, Kumar KR, Lang AE, Rossi M, van der Veen S, van de Warrenburg B, Warner T, Lohmann K, Klein C, Marras C, on behalf of the Task Force on Genetic Nomenclature in Movement Disorders. Nomenclature of Genetic Movement Disorders: Recommendations of the International Parkinson and Movement Disorder Society Task Force - An Update. Movement disorders : official journal of the Movement Disorder Society. 2022 May:37(5):905-935. doi: 10.1002/mds.28982. Epub 2022 Apr 28
[PubMed PMID: 35481685]
[6]
Timmers ER, Peall KJ, Dijk JM, Zutt R, Tijssen CC, Bergmans B, Foncke EM, Tijssen MAJ. Natural Course of Myoclonus-Dystonia in Adulthood: Stable Motor Signs But Increased Psychiatry. Movement disorders : official journal of the Movement Disorder Society. 2020 Jun:35(6):1077-1078. doi: 10.1002/mds.28033. Epub 2020 Mar 25
[PubMed PMID: 32212347]
[7]
Orsini A, Valetto A, Bertini V, Esposito M, Carli N, Minassian BA, Bonuccelli A, Peroni D, Michelucci R, Striano P. The best evidence for progressive myoclonic epilepsy: A pathway to precision therapy. Seizure. 2019 Oct:71():247-257. doi: 10.1016/j.seizure.2019.08.012. Epub 2019 Aug 23
[PubMed PMID: 31476531]
[8]
Saini V, Chalfin R, Leon J, Margolesky J. Pearls & Oy-sters: Bismuth neurotoxicity from use of topical bismuth dressing for burns. Neurology. 2019 Apr 2:92(14):680-681. doi: 10.1212/WNL.0000000000007236. Epub
[PubMed PMID: 30936231]
[9]
Barrett G. Jerk-locked averaging: technique and application. Journal of clinical neurophysiology : official publication of the American Electroencephalographic Society. 1992 Oct:9(4):495-508
[PubMed PMID: 1464676]
[10]
Sarrigiannis PG, Zis P, Unwin ZC, Blackburn DJ, Hoggard N, Zhao Y, Billings SA, Khan AA, Yianni J, Hadjivassiliou M. Tremor after long term lithium treatment; is it cortical myoclonus? Cerebellum & ataxias. 2019:6():5. doi: 10.1186/s40673-019-0100-y. Epub 2019 May 22
[PubMed PMID: 31143451]
[11]
Zhu XY, Tang XH, Yu H. Amiodarone-induced muscle tremor in an elderly patient: A case report. World journal of clinical cases. 2022 Dec 6:10(34):12726-12733. doi: 10.12998/wjcc.v10.i34.12726. Epub
[PubMed PMID: 36579101]
Level 3 (low-level) evidence
[12]
Chandarana M, Saraf U, Divya KP, Krishnan S, Kishore A. Myoclonus- A Review. Annals of Indian Academy of Neurology. 2021 May-Jun:24(3):327-338. doi: 10.4103/aian.AIAN_1180_20. Epub 2021 May 21
[PubMed PMID: 34446993]
[13]
Agarwal R, Baid R. Asterixis. Journal of postgraduate medicine. 2016 Apr-Jun:62(2):115-7. doi: 10.4103/0022-3859.180572. Epub
[PubMed PMID: 27089111]
[14]
Morimatsu M, Ono K, Harada A. Severe asterixis due to hypermagnesemia in chronic renal failure: a case report. Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology. 2021 Jun:42(6):2539-2542. doi: 10.1007/s10072-020-04945-x. Epub 2021 Jan 6
[PubMed PMID: 33404861]
Level 3 (low-level) evidence
[15]
Keita M, McIntyre K, Rodden LN, Schadt K, Lynch DR. Friedreich ataxia: clinical features and new developments. Neurodegenerative disease management. 2022 Oct:12(5):267-283. doi: 10.2217/nmt-2022-0011. Epub 2022 Jun 29
[PubMed PMID: 35766110]
[16]
Teive HAG, Camargo CHF, Munhoz RP. More than ataxia - Movement disorders in ataxia-telangiectasia. Parkinsonism & related disorders. 2018 Jan:46():3-8. doi: 10.1016/j.parkreldis.2017.12.009. Epub 2017 Dec 12
[PubMed PMID: 29249681]
[17]
Klockgether T, Mariotti C, Paulson HL. Spinocerebellar ataxia. Nature reviews. Disease primers. 2019 Apr 11:5(1):24. doi: 10.1038/s41572-019-0074-3. Epub 2019 Apr 11
[PubMed PMID: 30975995]
[18]
Olfati N, Shoeibi A, Litvan I. Clinical Spectrum of Tauopathies. Frontiers in neurology. 2022:13():944806. doi: 10.3389/fneur.2022.944806. Epub 2022 Jul 14
[PubMed PMID: 35911892]
[19]
Klawans HL, Goetz C, Bergen D. Levodopa-induced myoclonus. Archives of neurology. 1975 May:32(5):330-4
[PubMed PMID: 1079721]
[20]
Chen R, Berardelli A, Bhattacharya A, Bologna M, Chen KS, Fasano A, Helmich RC, Hutchison WD, Kamble N, Kühn AA, Macerollo A, Neumann WJ, Pal PK, Paparella G, Suppa A, Udupa K. Clinical neurophysiology of Parkinson's disease and parkinsonism. Clinical neurophysiology practice. 2022:7():201-227. doi: 10.1016/j.cnp.2022.06.002. Epub 2022 Jun 30
[PubMed PMID: 35899019]
[21]
Caballol N, Navarro-Otano J, Ávila A, Balagué-Marmaña M, Martínez-Fernández R, de Fàbregas O, Gelpí E, Valls-Solé J, Tolosa E. Myoclonus-Dominant Corticobasal Degeneration. Movement disorders clinical practice. 2018 Nov-Dec:5(6):649-652. doi: 10.1002/mdc3.12670. Epub 2018 Nov 6
[PubMed PMID: 30637289]
[22]
Grijalvo-Perez AM, Litvan I. Corticobasal degeneration. Seminars in neurology. 2014 Apr:34(2):160-73. doi: 10.1055/s-0034-1381734. Epub 2014 Jun 25
[PubMed PMID: 24963675]
[23]
Rowe JB, Holland N, Rittman T. Progressive supranuclear palsy: diagnosis and management. Practical neurology. 2021 Oct:21(5):376-383. doi: 10.1136/practneurol-2020-002794. Epub 2021 Jul 2
[PubMed PMID: 34215700]
[24]
Bluett B, Pantelyat AY, Litvan I, Ali F, Apetauerova D, Bega D, Bloom L, Bower J, Boxer AL, Dale ML, Dhall R, Duquette A, Fernandez HH, Fleisher JE, Grossman M, Howell M, Kerwin DR, Leegwater-Kim J, Lepage C, Ljubenkov PA, Mancini M, McFarland NR, Moretti P, Myrick E, Patel P, Plummer LS, Rodriguez-Porcel F, Rojas J, Sidiropoulos C, Sklerov M, Sokol LL, Tuite PJ, VandeVrede L, Wilhelm J, Wills AA, Xie T, Golbe LI. Best Practices in the Clinical Management of Progressive Supranuclear Palsy and Corticobasal Syndrome: A Consensus Statement of the CurePSP Centers of Care. Frontiers in neurology. 2021:12():694872. doi: 10.3389/fneur.2021.694872. Epub 2021 Jul 1
[PubMed PMID: 34276544]
Level 3 (low-level) evidence
[25]
Höglinger GU, Respondek G, Stamelou M, Kurz C, Josephs KA, Lang AE, Mollenhauer B, Müller U, Nilsson C, Whitwell JL, Arzberger T, Englund E, Gelpi E, Giese A, Irwin DJ, Meissner WG, Pantelyat A, Rajput A, van Swieten JC, Troakes C, Antonini A, Bhatia KP, Bordelon Y, Compta Y, Corvol JC, Colosimo C, Dickson DW, Dodel R, Ferguson L, Grossman M, Kassubek J, Krismer F, Levin J, Lorenzl S, Morris HR, Nestor P, Oertel WH, Poewe W, Rabinovici G, Rowe JB, Schellenberg GD, Seppi K, van Eimeren T, Wenning GK, Boxer AL, Golbe LI, Litvan I, Movement Disorder Society-endorsed PSP Study Group. Clinical diagnosis of progressive supranuclear palsy: The movement disorder society criteria. Movement disorders : official journal of the Movement Disorder Society. 2017 Jun:32(6):853-864. doi: 10.1002/mds.26987. Epub 2017 May 3
[PubMed PMID: 28467028]
[26]
Beagle AJ, Darwish SM, Ranasinghe KG, La AL, Karageorgiou E, Vossel KA. Relative Incidence of Seizures and Myoclonus in Alzheimer's Disease, Dementia with Lewy Bodies, and Frontotemporal Dementia. Journal of Alzheimer's disease : JAD. 2017:60(1):211-223. doi: 10.3233/JAD-170031. Epub
[PubMed PMID: 28826176]
[27]
Neri S, Mastroianni G, Gardella E, Aguglia U, Rubboli G. Epilepsy in neurodegenerative diseases. Epileptic disorders : international epilepsy journal with videotape. 2022 Apr 1:24(2):249-273. doi: 10.1684/epd.2021.1406. Epub
[PubMed PMID: 35596580]
[28]
Gurram S, Holla VV, Sharma P, Kamble N, Saini J, Netravathi M, Yadav R, Pal PK. Spectrum and Pattern of Movement Disorders in Patients with Sporadic Creutzfeldt-Jakob Disease. Tremor and other hyperkinetic movements (New York, N.Y.). 2023:13():14. doi: 10.5334/tohm.753. Epub 2023 May 3
[PubMed PMID: 37152622]
[29]
Termsarasab P, Pitakpatapee Y, Frucht SJ, Srivanitchapoom P. Steroid-responsive Encephalopathy Associated with Autoimmune Thyroiditis (SREAT) Presenting with Pure Cerebellar Ataxia. Tremor and other hyperkinetic movements (New York, N.Y.). 2018:8():585. doi: 10.7916/D8CZ4QQQ. Epub 2018 Aug 9
[PubMed PMID: 30191089]
[30]
Schneider SA, Tschaidse L, Reisch N. Thyroid Disorders and Movement Disorders-A Systematic Review. Movement disorders clinical practice. 2023 Mar:10(3):360-368. doi: 10.1002/mdc3.13656. Epub 2023 Feb 3
[PubMed PMID: 36949803]
Level 1 (high-level) evidence
[31]
Mattozzi S, Sabater L, Escudero D, Ariño H, Armangue T, Simabukuro M, Iizuka T, Hara M, Saiz A, Sotgiu S, Dalmau J, Graus F. Hashimoto encephalopathy in the 21st century. Neurology. 2020 Jan 14:94(2):e217-e224. doi: 10.1212/WNL.0000000000008785. Epub 2019 Dec 27
[PubMed PMID: 31882532]
[32]
Abboud H, Probasco JC, Irani S, Ances B, Benavides DR, Bradshaw M, Christo PP, Dale RC, Fernandez-Fournier M, Flanagan EP, Gadoth A, George P, Grebenciucova E, Jammoul A, Lee ST, Li Y, Matiello M, Morse AM, Rae-Grant A, Rojas G, Rossman I, Schmitt S, Venkatesan A, Vernino S, Pittock SJ, Titulaer MJ, Autoimmune Encephalitis Alliance Clinicians Network. Autoimmune encephalitis: proposed best practice recommendations for diagnosis and acute management. Journal of neurology, neurosurgery, and psychiatry. 2021 Jul:92(7):757-768. doi: 10.1136/jnnp-2020-325300. Epub 2021 Mar 1
[PubMed PMID: 33649022]
[33]
Flanagan EP, Geschwind MD, Lopez-Chiriboga AS, Blackburn KM, Turaga S, Binks S, Zitser J, Gelfand JM, Day GS, Dunham SR, Rodenbeck SJ, Clardy SL, Solomon AJ, Pittock SJ, McKeon A, Dubey D, Zekeridou A, Toledano M, Turner LE, Vernino S, Irani SR. Autoimmune Encephalitis Misdiagnosis in Adults. JAMA neurology. 2023 Jan 1:80(1):30-39. doi: 10.1001/jamaneurol.2022.4251. Epub
[PubMed PMID: 36441519]
[34]
Bhagavati S. Autoimmune Disorders of the Nervous System: Pathophysiology, Clinical Features, and Therapy. Frontiers in neurology. 2021:12():664664. doi: 10.3389/fneur.2021.664664. Epub 2021 Apr 14
[PubMed PMID: 33935958]
[35]
Balint B, Vincent A, Meinck HM, Irani SR, Bhatia KP. Movement disorders with neuronal antibodies: syndromic approach, genetic parallels and pathophysiology. Brain : a journal of neurology. 2018 Jan 1:141(1):13-36. doi: 10.1093/brain/awx189. Epub
[PubMed PMID: 29053777]
[36]
Bastiaansen AEM, van Steenhoven RW, Te Vaarwerk ES, van der Flier WM, Teunissen C, de Graaff E, Nagtzaam MMP, Paunovic M, Franken SC, Schreurs MWJ, Leypoldt F, Smitt PAE, de Vries JM, Seelaar H, van Swieten J, Jan de Jong F, Pijnenburg YAL, Titulaer MJ. Antibodies Associated With Autoimmune Encephalitis in Patients With Presumed Neurodegenerative Dementia. Neurology(R) neuroimmunology & neuroinflammation. 2023 Sep:10(5):. doi: 10.1212/NXI.0000000000200137. Epub 2023 Jun 13
[PubMed PMID: 37311646]
[37]
Graus F, Vogrig A, Muñiz-Castrillo S, Antoine JG, Desestret V, Dubey D, Giometto B, Irani SR, Joubert B, Leypoldt F, McKeon A, Prüss H, Psimaras D, Thomas L, Titulaer MJ, Vedeler CA, Verschuuren JJ, Dalmau J, Honnorat J. Updated Diagnostic Criteria for Paraneoplastic Neurologic Syndromes. Neurology(R) neuroimmunology & neuroinflammation. 2021 Jul:8(4):. doi: 10.1212/NXI.0000000000001014. Epub 2021 May 18
[PubMed PMID: 34006622]
[38]
Vogrig A, Gigli GL, Segatti S, Corazza E, Marini A, Bernardini A, Valent F, Fabris M, Curcio F, Brigo F, Iacono D, Passadore P, Rana M, Honnorat J, Valente M. Epidemiology of paraneoplastic neurological syndromes: a population-based study. Journal of neurology. 2020 Jan:267(1):26-35. doi: 10.1007/s00415-019-09544-1. Epub 2019 Sep 24
[PubMed PMID: 31552550]
[39]
Jitprapaikulsan J, Paul P, Thakolwiboon S, Mittal SO, Pittock SJ, Dubey D. Paraneoplastic neurological syndrome: an evolving story. Neuro-oncology practice. 2021 Aug:8(4):362-374. doi: 10.1093/nop/npab002. Epub 2021 Feb 24
[PubMed PMID: 34277016]
[40]
Kitazaki Y, Ikawa M, Kishitani T, Kamisawa T, Nakane S, Nakamoto Y, Hamano T. Progressive Encephalomyelitis with Rigidity and Myoclonus (PERM)-like Symptoms Associated with Anti-ganglionic Acetylcholine Receptor Antibodies. Internal medicine (Tokyo, Japan). 2021 Jul 15:60(14):2307-2313. doi: 10.2169/internalmedicine.6419-20. Epub 2021 Feb 15
[PubMed PMID: 33583893]
[41]
Zhang X, Yan W, Song Y, Zhu H, Sun Y. Adult-onset idiopathic opsoclonus-myoclonus syndrome. Arquivos brasileiros de oftalmologia. 2023 Mar 24:():. pii: S0004-27492023005002304. doi: 10.5935/0004-2749.2022-0024. Epub 2023 Mar 24
[PubMed PMID: 36995813]
[42]
Oh SY, Kim JS, Dieterich M. Update on opsoclonus-myoclonus syndrome in adults. Journal of neurology. 2019 Jun:266(6):1541-1548. doi: 10.1007/s00415-018-9138-7. Epub 2018 Nov 27
[PubMed PMID: 30483882]
[43]
Adamaszek M, Langner S, Mehrholz J, Heiinrich A. Opsoclonus-Myoclonus-Ataxia Syndrome Due to Covid-19. Cerebellum (London, England). 2023 Oct 9:():. doi: 10.1007/s12311-023-01610-9. Epub 2023 Oct 9
[PubMed PMID: 37814146]
[44]
Ben Mohamed D, Zouari R, Ketata J, Nabli F, Blel S, Ben Sassi S. Myoclonus status revealing COVID 19 infection. Seizure. 2023 Jan:104():12-14. doi: 10.1016/j.seizure.2022.11.010. Epub 2022 Nov 22
[PubMed PMID: 36446232]
[45]
Rass V, Lindner A, Beer R, Helbok R, Pfausler B. Letter to the editor: Adult-onset opsoclonus-myoclonus syndrome due to tick-borne encephalitis virus. Acta neurologica Belgica. 2023 Aug 17:():. doi: 10.1007/s13760-023-02362-3. Epub 2023 Aug 17
[PubMed PMID: 37587266]
Level 3 (low-level) evidence
[46]
Hill KA, Peters JJ, Schaefer SM. Myoclonic status epilepticus after severe hyperthermia in a patient with coronavirus disease 2019. Acute and critical care. 2023 Nov:38(4):509-512. doi: 10.4266/acc.2021.01452. Epub 2022 Mar 24
[PubMed PMID: 35545241]
[47]
Scheibe F, Neumann WJ, Lange C, Scheel M, Furth C, Köhnlein M, Mergenthaler P, Schultze-Amberger J, Triebkorn P, Ritter P, Kühn AA, Meisel A. Movement disorders after hypoxic brain injury following cardiac arrest in adults. European journal of neurology. 2020 Oct:27(10):1937-1947. doi: 10.1111/ene.14326. Epub 2020 Jun 26
[PubMed PMID: 32416613]
[48]
Guo Y, Xiao Y, Chen LF, Yin DH, Wang RD. Lance Adams syndrome: two cases report and literature review. The Journal of international medical research. 2022 Feb:50(2):3000605211059933. doi: 10.1177/03000605211059933. Epub
[PubMed PMID: 35220777]
Level 3 (low-level) evidence
[49]
Asghar A, Barnes B, Aburahma A, Khan S, Primera G, Ravikumar N. Post hypoxic myoclonus: A tale of two minds. Epilepsy & behavior reports. 2023:21():100589. doi: 10.1016/j.ebr.2023.100589. Epub 2023 Jan 21
[PubMed PMID: 36747905]
[50]
Zutt R, Elting JW, Tijssen MAJ. Tremor and myoclonus. Handbook of clinical neurology. 2019:161():149-165. doi: 10.1016/B978-0-444-64142-7.00046-1. Epub
[PubMed PMID: 31307597]
[51]
Beudel M, Zutt R, Meppelink AM, Little S, Elting JW, Stelten BML, Edwards M, Tijssen MAJ. Improving neurophysiological biomarkers for functional myoclonic movements. Parkinsonism & related disorders. 2018 Jun:51():3-8. doi: 10.1016/j.parkreldis.2018.03.029. Epub 2018 Apr 6
[PubMed PMID: 29653908]
[52]
Constantinides VC, Paraskevas GP, Paraskevas PG, Stefanis L, Kapaki E. Corticobasal degeneration and corticobasal syndrome: A review. Clinical parkinsonism & related disorders. 2019:1():66-71. doi: 10.1016/j.prdoa.2019.08.005. Epub 2019 Aug 30
[PubMed PMID: 34316603]
[53]
Lyons S, Trépel D, Lynch T, Walsh R, O'Dowd S. The prevalence and incidence of progressive supranuclear palsy and corticobasal syndrome: a systematic review and meta-analysis. Journal of neurology. 2023 Sep:270(9):4451-4465. doi: 10.1007/s00415-023-11791-2. Epub 2023 Jun 8
[PubMed PMID: 37289323]
Level 1 (high-level) evidence
[54]
Caviness JN. Epidemiology of myoclonus. Advances in neurology. 2002:89():19-22
[PubMed PMID: 11968444]
Level 3 (low-level) evidence
[55]
Zutt R, Elting JW, van Zijl JC, van der Hoeven JH, Roosendaal CM, Gelauff JM, Peall KJ, Tijssen MAJ. Electrophysiologic testing aids diagnosis and subtyping of myoclonus. Neurology. 2018 Feb 20:90(8):e647-e657. doi: 10.1212/WNL.0000000000004996. Epub 2018 Jan 19
[PubMed PMID: 29352095]
[56]
Kozlov M. Famous 'homunculus' brain map redrawn to include complex movements. Nature. 2023 Apr 19:():. doi: 10.1038/d41586-023-01312-6. Epub 2023 Apr 19
[PubMed PMID: 37076715]
[57]
Lozsadi D. Myoclonus: a pragmatic approach. Practical neurology. 2012 Aug:12(4):215-24. doi: 10.1136/practneurol-2011-000107. Epub
[PubMed PMID: 22869763]
[58]
Rossi M, van der Veen S, Merello M, Tijssen MAJ, van de Warrenburg B. Myoclonus-Ataxia Syndromes: A Diagnostic Approach. Movement disorders clinical practice. 2021 Jan:8(1):9-24. doi: 10.1002/mdc3.13106. Epub 2020 Nov 3
[PubMed PMID: 33426154]
[60]
Atarashi R. RT-QuIC as ultrasensitive method for prion detection. Cell and tissue research. 2023 Apr:392(1):295-300. doi: 10.1007/s00441-021-03568-8. Epub 2022 Jan 27
[PubMed PMID: 35084571]
[61]
Gardella E, Møller RS. Phenotypic and genetic spectrum of SCN8A-related disorders, treatment options, and outcomes. Epilepsia. 2019 Dec:60 Suppl 3():S77-S85. doi: 10.1111/epi.16319. Epub
[PubMed PMID: 31904124]
[62]
Howard P, Remi J, Remi C, Charlesworth S, Whalley H, Bhatia R, Hitchens M, Mihalyo M, Wilcock A. Levetiracetam. Journal of pain and symptom management. 2018 Oct:56(4):645-649. doi: 10.1016/j.jpainsymman.2018.07.012. Epub 2018 Jul 21
[PubMed PMID: 30036676]
[63]
Iijima M, Oguni H, Kobayashi M, Kitagawa K. Perampanel improved intractable myoclonus in two patients with myoclonus epilepsy. eNeurologicalSci. 2019 Dec:17():100215. doi: 10.1016/j.ensci.2019.100215. Epub 2019 Nov 18
[PubMed PMID: 31799456]
[64]
Assenza G, Nocerino C, Tombini M, Di Gennaro G, D'Aniello A, Verrotti A, Marrelli A, Ricci L, Lanzone J, Di Lazzaro V, Bilo L, Coppola A. Perampanel Improves Cortical Myoclonus and Disability in Progressive Myoclonic Epilepsies: A Case Series and a Systematic Review of the Literature. Frontiers in neurology. 2021:12():630366. doi: 10.3389/fneur.2021.630366. Epub 2021 Mar 24
[PubMed PMID: 33841303]
Level 1 (high-level) evidence
[65]
Oi K, Neshige S, Hitomi T, Kobayashi K, Tojima M, Matsuhashi M, Shimotake A, Fujii D, Matsumoto R, Kasama S, Kanda M, Wada Y, Maruyama H, Takahashi R, Ikeda A. Low-dose perampanel improves refractory cortical myoclonus by the dispersed and suppressed paroxysmal depolarization shifts in the sensorimotor cortex. Clinical neurophysiology : official journal of the International Federation of Clinical Neurophysiology. 2019 Oct:130(10):1804-1812. doi: 10.1016/j.clinph.2019.07.006. Epub 2019 Jul 19
[PubMed PMID: 31401489]
[66]
Bianchini S, Bellantoni G, Albergati A, Magrassi L. Postsurgical cortical myoclonus responsive to perampanel. Neurology. Clinical practice. 2018 Apr:8(2):159-161. doi: 10.1212/CPJ.0000000000000440. Epub
[PubMed PMID: 29708211]
[67]
Hainque E, Vidailhet M, Cozic N, Charbonnier-Beaupel F, Thobois S, Tranchant C, Brochard V, Glibert G, Drapier S, Mutez E, Doe De Maindreville A, Lebouvier T, Hubsch C, Degos B, Bonnet C, Grabli D, Legrand AP, Méneret A, Azulay JP, Bissery A, Zahr N, Clot F, Mallet A, Dupont S, Apartis E, Corvol JC, Roze E. A randomized, controlled, double-blind, crossover trial of zonisamide in myoclonus-dystonia. Neurology. 2016 May 3:86(18):1729-35. doi: 10.1212/WNL.0000000000002631. Epub 2016 Apr 6
[PubMed PMID: 27053715]
Level 1 (high-level) evidence
[68]
Ahmed HS. Post-hypoxic myoclonus; what we know and gaps in knowledge. Tropical doctor. 2023 Oct:53(4):460-463. doi: 10.1177/00494755231181153. Epub 2023 Jun 7
[PubMed PMID: 37287278]
[69]
Zhang YQ, Wang JW, Wang YP, Zhang XH, Li JP. Thalamus Stimulation for Myoclonus Dystonia Syndrome: Five Cases and Long-Term Follow-up. World neurosurgery. 2019 Feb:122():e933-e939. doi: 10.1016/j.wneu.2018.10.177. Epub 2018 Nov 10
[PubMed PMID: 30419400]
Level 3 (low-level) evidence
[70]
Krause P, Koch K, Gruber D, Kupsch A, Gharabaghi A, Schneider GH, Kühn AA. Long-term effects of pallidal and thalamic deep brain stimulation in myoclonus dystonia. European journal of neurology. 2021 May:28(5):1566-1573. doi: 10.1111/ene.14737. Epub 2021 Feb 6
[PubMed PMID: 33452690]
[71]
Besa Lehmann V, Rosenbaum M, Bulman DE, Read T, Verhagen Metman L. A Case Report of Myoclonus-Dystonia with Isolated Myoclonus Phenotype and Novel Mutation Successfully Treated with Deep Brain Stimulation. Neurology and therapy. 2020 Jun:9(1):187-191. doi: 10.1007/s40120-020-00186-4. Epub 2020 Apr 9
[PubMed PMID: 32274660]
Level 3 (low-level) evidence
[72]
Kosutzka Z, Tisch S, Bonnet C, Ruiz M, Hainque E, Welter ML, Viallet F, Karachi C, Navarro S, Jahanshahi M, Rivaud-Pechoux S, Grabli D, Roze E, Vidailhet M. Long-term GPi-DBS improves motor features in myoclonus-dystonia and enhances social adjustment. Movement disorders : official journal of the Movement Disorder Society. 2019 Jan:34(1):87-94. doi: 10.1002/mds.27474. Epub 2018 Oct 9
[PubMed PMID: 30302819]
[73]
Nardone R, Versace V, Höller Y, Sebastianelli L, Brigo F, Lochner P, Golaszewski S, Saltuari L, Trinka E. Transcranial magnetic stimulation in myoclonus of different aetiologies. Brain research bulletin. 2018 Jun:140():258-269. doi: 10.1016/j.brainresbull.2018.05.016. Epub 2018 May 24
[PubMed PMID: 29803873]
[74]
Pranzatelli MR. Advances in Biomarker-Guided Therapy for Pediatric- and Adult-Onset Neuroinflammatory Disorders: Targeting Chemokines/Cytokines. Frontiers in immunology. 2018:9():557. doi: 10.3389/fimmu.2018.00557. Epub 2018 Apr 4
[PubMed PMID: 29670611]
Level 3 (low-level) evidence
[75]
Grandas F. Hemiballismus. Handbook of clinical neurology. 2011:100():249-60. doi: 10.1016/B978-0-444-52014-2.00017-3. Epub
[PubMed PMID: 21496584]
[76]
Dreissen YEM, Cath DC, Tijssen MAJ. Functional jerks, tics, and paroxysmal movement disorders. Handbook of clinical neurology. 2016:139():247-258. doi: 10.1016/B978-0-12-801772-2.00021-7. Epub
[PubMed PMID: 27719843]
[77]
Caviness JN, Brown P. Myoclonus: current concepts and recent advances. The Lancet. Neurology. 2004 Oct:3(10):598-607
[PubMed PMID: 15380156]
Level 3 (low-level) evidence